Genzyme withdraws offer for development partnership
This article was originally published in Clinica
US biotechnology company Genzyme has withdrawn its offer to acquire, in a stock swap, all the assets of Genzyme Development Partners, also known as the Surgical Aids Partnership). Genzyme had offered to purchase the partnership in February for $93 million in Genzyme shares (see Clinica No 691, p 10).
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.